Age: 41.0
Sex: M
Vaccine: SMALLMNK
Symptoms: Extra dose administered, Incorrect route of product administration, No adverse event
Clinical narrative: The second dose of Jynneos was administered 29 days after the first dose of Jynneos; The patient received the third dose of Jynneos; The patient received three doses of Jynneos intradermally; Case reference number US-BN-2024-001814 is a spontaneous case report initially received from a nurse via Med Communication (reference number: USBAV24-0771) on 18-Apr-2024 and concerns *a 43-year-old male patient.*  *The patient's current medical conditions included human immunodeficiency virus (HIV) infection, allergy to penicillin with reaction reported as swelling and allergy to sulfa trimethropim with reaction reported as anphylaxis.*  The patient's concomitant medication details were not provided.  On 14-Sep-2022, the patient was vaccinated with the first dose of Jynneos *(batch number: FDP00005; expiration date: 31-Aug-2023), at 0.1 ml, intradermally, at right arm, for indication reported as monkeypox vaccine (explicitly coded as 'intradermal injection').*  On 13-Oct-2022, 29 days after the first dose of Jynneos, the patient was vaccinated with the second dose of Jynneos *(batch number: FDP00013; expiration date: 30-Sep-2024), at 0.1 ml, intradermally, at left arm* (explicitly coded as 'inappropriate schedule of vaccine administered' *and 'intradermal injection'*).  On 29-Mar-2024, 533 days after the second dose, the patient was vaccinated with the third dose of Jynneos *(batch number: FDP00009; expiration date: 30-May-2024), at 0.1 ml, intradermally, at right arm* (explicitly coded as 'extra dose administered' *and 'intradermal injection'). As reported, the administration of the third dose was a human error as it was overlooked that the patient had received monkeypox vaccine previously.*  *As reported, the patient did not experience any adverse event due to Jynneos vaccine.*  Additional information received from Bavarian Nordic on 18-Apr-2024 included local BN case ID.  Additional information received from a Med Communications on 18-Apr-2024 included an additional Med Communications reference number (USBAV24-0771).  All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).  Follow-up information received from other healthcare professional on 26-Apr-2024: New information included patient demographic details, medical history, vaccination details for the three administered doses of Jynneos due to which intradermal injection was coded and confirmation that the patient did not experience any adverse event.; Reporter's Comments: A 43-year-old male patient was vaccinated with the second dose of Jynneos, intradermally at left arm, 29 days after the first dose for an unknown indication, which is considered as inappropriate schedule of vaccine administered and  intradermal injection. 533 days after the second dose, the patient was vaccinated with the third dose of Jynneos at 0.1 ml, intradermally, at right arm which is considered as extra dose administered and intradermal injection. No associated adverse events were reported. Inappropriate schedule of vaccine administered, injection and extra dose administered are listed per company convention. The patient's current medical conditions included human immunodeficiency virus (HIV) infection, allergy to penicillin with reaction reported as swelling and allergy to sulfa trimethropim with reaction reported as anphylaxis while concomitant medication details were not provided. Inappropriate schedule of vaccine administered, injection and extra dose administered are not related to Jynneos, but to a human factor. The case is non-serious.; Sender's Comments: A 43-year-old male patient was vaccinated with the second dose of Jynneos, intradermally at left arm, 29 days after the first dose for an unknown indication, which is considered as inappropriate schedule of vaccine administered and  intradermal injection. 533 days after the second dose, the patient was vaccinated with the third dose of Jynneos at 0.1 ml, intradermally, at right arm which is considered as extra dose administered and intradermal injection. No associated adverse events were reported. Inappropriate schedule of vaccine administered, injection and extra dose administered are listed per company convention. The patient's current medical conditions included human immunodeficiency virus (HIV) infection, allergy to penicillin with reaction reported as swelling and allergy to sulfa trimethropim with reaction reported as anphylaxis while concomitant medication details were not provided. Inappropriate schedule of vaccine administered, injection and extra dose administered are not related to Jynneos, but to a human factor. The case is non-serious.